SCHEMBL25969296

SCHEMBL25969296

O=C(O)c1cccc2c1cnn2CCC(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 6/20 0.44
KMO O15229 1/20 0.40
CCR1 P32246 4/20 0.38
SCN9A Q15858 1/20 0.38
SCN10A Q9Y5Y9 1/20 0.38
KDM4E B2RXH2 2/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
POLB P06746 2/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4A O75164 1/20 0.35
RAB9A P51151 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
HIF1AN Q9NWT6 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NR4A1 P22736 1/20 0.35
NR4A2 P43354 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15999099 0.86 SCN9A (0.49) KDM4CKMOSCN9ASCN10AKDM4E
SCHEMBL30547754 0.83 KMO (0.43) KDM4CKMOKDM4EHPGDHSD17B10
SCHEMBL25966972 0.82 KDM4C (0.48) KDM4CKMOKDM4EHPGDHSD17B10
SCHEMBL30622483 0.79 HPGD (0.41) KDM4CKMOKDM4EHPGDHSD17B10
SCHEMBL15999085 0.78 KDM4E (0.40) KDM4CKMOKDM4EHPGDHSD17B10
SCHEMBL30622472 0.78 POLB (0.41) KDM4CKMOKDM4EHPGDHSD17B10
SCHEMBL30622541 0.78 KDM4C (0.51) KDM4CKMOKDM4EHPGDHSD17B10
SCHEMBL15999091 0.78 KDM4E (0.39) KDM4CKMOCCR1SCN9ASCN10A
SCHEMBL15999071 0.78 CYP11B2 (0.46) CCR1SCN9ASCN10AKDM4EHSD17B10
SCHEMBL15999052 0.77 PTGER4 (0.50) CCR1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250088-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250088-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 KDM4C 4078/4885KMO 4168/4885CCR1 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.